Sepsis ImmunoScore™, a diagnostic tool designed by Prenosis for early sepsis prediction, has been awarded a BARDA contract to demonstrate its clinical value.
Prenosis Inc., an artificial intelligence company enabling precision medicine in acute care, has been awarded a BARDA contract for studying the utility of its Sepsis ImmunoScore™, a pathogen-agnostic, host-based digital diagnostic tool for the early detection of sepsis.
The contract is allocated to a clinical study of the Sepsis ImmunoScore™ with the objectives to assess the feasibility of implementing the Sepsis ImmunoScore™ in hospitals. Prenosis’ Sepsis ImmunoScore™ uses AI/ML to assess a patient's risk of sepsis within 24 hours based on protein biomarkers and clinical parameters. Prenosis has built a large, rapidly growing biobank and hybrid biomarker-clinical dataset from patients with sepsis and other infections. By leveraging Aidbox as a FHIR backend platform, Prenosis transformed this comprehensive information into a practical tool that has the potential to enable optimized and personalized care for patients.
Sepsis, a life-threatening systemic response to infection, is estimated by the WHO to cause 1 in 5 deaths worldwide. In the United States alone, the annual cost for sepsis treatment nears a staggering $62 billion, marking it as one of the largest cost drivers for U.S. hospitals.
The Sepsis ImmunoScore™ seamlessly integrates with existing Hospital EHRs and utilizes Aidbox’s data integration and management capabilities with the potential to empower physicians to diagnose sepsis faster and begin treatment sooner. This diagnostic tool generates a sepsis risk score, assigns risk categories, and provides extra information. This data can be easily accessed through a hospital's electronic medical record system (EMR) or a user-friendly web interface.
The next important step in popularizing and integrating the Sepsis ImmunoScore™ is to demonstrate its practical benefits in a clinical setting. The BARDA award will fund a study conducted at three hospitals, where the implementation of the Sepsis ImmunoScore™ will be assessed in real-time, evaluating its impact on clinical decision-making and patient outcomes, thereby affirming its value.
"We're pleased to partner with Prenosis on this innovative project that has the potential to change the paradigm of sepsis prediction during the minutes that matter, and, most importantly, save lives," said Pavel Smirnov, CEO at Health Samurai.
FHIR® is the registered trademark of HL7.
Prenosis is a health tech innovator devoted to ushering in a new era of precision medicine in acute care. Its Immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. Its proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care.
About Health Samurai
Health Samurai helps healthcare providers, health plans, IT vendors, and digital health startups develop FHIR-native solutions based on the Aidbox FHIR Platform. Since 2012, Aidbox has served as a solid backbone for 100+ solutions: specialty EHRs, care coordination systems, telemedicine solutions, CDRs, and data analytics platforms worldwide.